In terms of postoperative adjuvant chemotherapy, sequential atezolizumab after adjuvant chemotherapy was approved on October 2021 by the FDA and recommended in the NCCN guidelines as the first perioperative ICI for PD-L1-positive (≥1%) stage II-IIIA NSCLC after radical resection based on the results of the IMpower010 trial (6). The gene discussed is CD274; the disease is non-small cell lung carcinoma.